



Talpher to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 05, 2024

SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talpher, Inc. (Nasdaq: TLPH), ("Talpher"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.

The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET [here](#) or by visiting the Investors section of the Company's website at www.talpher.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section.

About Talpher, Inc.

Talpher, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talpher's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talpher, please visit www.talpher.com.



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/talpher-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239931.html>

SOURCE Talpher, Inc.

Investor Contacts: Talpher: Raffi Asadorian, CFO, 650-216-3500, investors@talpher.com; LifeSci Advisors, Kevin Gardner, 617-283-2856, kgardner@lifesciadvisors.com; Chris Calabrese, 917-680-5608, ccalabrese@lifesciadvisors.com